AR032422A1 - Uso de inhibidores de il-18 para el tratamiento y/o prevencion de la enfermedad cardiaca - Google Patents

Uso de inhibidores de il-18 para el tratamiento y/o prevencion de la enfermedad cardiaca

Info

Publication number
AR032422A1
AR032422A1 ARP020100315A ARP020100315A AR032422A1 AR 032422 A1 AR032422 A1 AR 032422A1 AR P020100315 A ARP020100315 A AR P020100315A AR P020100315 A ARP020100315 A AR P020100315A AR 032422 A1 AR032422 A1 AR 032422A1
Authority
AR
Argentina
Prior art keywords
prevention
treatment
inhibitors
cardiac disease
heart disease
Prior art date
Application number
ARP020100315A
Other languages
English (en)
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of AR032422A1 publication Critical patent/AR032422A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Uso de un inhibidor de IL-18 en la preparacion de un medicamento para tratamiento y/ o prevencion de una enfermedad cardiaca, en particular enfermedad cardiaca isquémica, las combinaciones de un inhibidor de II-18 o un antagonista de TNF son consideradas también para el tratamiento y/ o prevencion de una enfermedad cardíaca.
ARP020100315A 2001-01-29 2002-01-29 Uso de inhibidores de il-18 para el tratamiento y/o prevencion de la enfermedad cardiaca AR032422A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01101959 2001-01-29

Publications (1)

Publication Number Publication Date
AR032422A1 true AR032422A1 (es) 2003-11-05

Family

ID=8176323

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020100315A AR032422A1 (es) 2001-01-29 2002-01-29 Uso de inhibidores de il-18 para el tratamiento y/o prevencion de la enfermedad cardiaca

Country Status (32)

Country Link
US (1) US20040234523A1 (es)
EP (1) EP1355668B1 (es)
JP (2) JP4860897B2 (es)
KR (1) KR100857376B1 (es)
CN (1) CN1326562C (es)
AR (1) AR032422A1 (es)
AT (1) ATE380558T1 (es)
BG (1) BG66483B1 (es)
BR (1) BR0206819A (es)
CA (1) CA2435466C (es)
CY (1) CY1107203T1 (es)
CZ (1) CZ305653B6 (es)
DE (1) DE60224004T2 (es)
DK (1) DK1355668T3 (es)
EA (2) EA006767B1 (es)
EE (1) EE05534B1 (es)
ES (1) ES2295332T3 (es)
HK (1) HK1062810A1 (es)
HR (1) HRP20030609A2 (es)
HU (1) HU229164B1 (es)
IL (2) IL157024A0 (es)
ME (1) ME00549B (es)
MX (1) MXPA03006776A (es)
NO (1) NO331083B1 (es)
PL (1) PL213568B1 (es)
PT (1) PT1355668E (es)
RS (1) RS51125B (es)
SI (1) SI1355668T1 (es)
SK (1) SK287620B6 (es)
UA (1) UA80676C2 (es)
WO (1) WO2002060479A1 (es)
ZA (1) ZA200305439B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI335336B (es) 2000-02-10 2011-01-01 Abbott Gmbh & Co Kg
EP1331943A4 (en) 2000-10-11 2005-01-26 Viron Therapeutics Inc NUCLEIC ACID MOLECULES AND POLYPEPTIDES FOR IMMUNOMODULATION
US7718368B2 (en) 2000-12-04 2010-05-18 Viron Therapeutics Inc. Immunomodulatory protein and useful embodiments thereof
JP5074030B2 (ja) 2003-05-13 2012-11-14 メルク セローノ ソシエテ アノニム Ｉｌ−１８結合タンパク質の活性変異体とその医学的応用
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
JP4961559B2 (ja) * 2004-03-11 2012-06-27 友昭 星野 インターロイキン１８阻害剤を有効成分とする疾患の予防又は治療剤
DK2267024T3 (da) 2005-06-03 2012-06-25 Ares Trading Sa Fremstilling af rekombinant II-18 bindingsprotein
PL1891088T3 (pl) 2005-06-10 2012-03-30 Ares Trading Sa Sposób oczyszczania białka wiążącego IL-18
AU2008324814B2 (en) * 2007-11-05 2013-05-16 Solventum Intellectual Properties Company Identification of tissue for debridement
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
MX2016002719A (es) * 2013-09-05 2016-09-06 Ab2 Bio Sa Proteina de union a interleucina 18 (il-18bp) en enfermedades inflamatorias.
MY194040A (en) 2015-03-05 2022-11-09 Ab2 Bio Sa Il-18 binding protein (il-18bp) and antibodies in inflammatory diseases
US11091795B2 (en) 2016-07-11 2021-08-17 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for diagnosing and treating arrhythmias

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204261B1 (en) * 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
NZ322197A (en) * 1995-11-21 1999-02-25 Yamanouchi Pharma Co Ltd Pyrido[2,3-d] pyrimidine derivatives and pharmaceutical compositions thereof
ATE310528T1 (de) * 1996-09-12 2005-12-15 Idun Pharmaceuticals Inc Hemmung der apoptose unter verwendung von inhibitoren der interleukin-1 beta converting enzym (ice)/ced-3 familie
DE69736984T2 (de) * 1996-12-06 2007-09-13 Vertex Pharmaceuticals Inc., Cambridge Inhibitoren des interleukin-1-beta konvertierenden enzyms
CA2282845A1 (en) * 1997-03-18 1998-09-24 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
DE19743687C1 (de) * 1997-10-06 1998-11-26 Henkel Kgaa Detergensgemische und deren Verwendung
AU4961499A (en) * 1998-06-26 2000-01-17 Eli Lilly And Company 5-HT1f agonists
CA2340579A1 (en) * 1998-09-01 2000-03-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin 18-binding protein
EP1022027A1 (en) * 1999-01-22 2000-07-26 Applied Research Systems ARS Holding N.V. Tumor necrosis factor antagonists and their use in endometriosis
AU3876600A (en) * 1999-03-16 2000-10-04 Cytovia, Inc. Substituted 2-aminobenzamide caspase inhibitors and the use thereof
AU4213500A (en) * 1999-04-09 2000-11-14 Cytovia, Inc. Caspase inhibitors and the use thereof
AU6078500A (en) * 1999-07-09 2001-01-30 Amgen, Inc. Combination therapy for conditions leading to bone loss
TWI335336B (es) * 2000-02-10 2011-01-01 Abbott Gmbh & Co Kg
UA87658C2 (uk) * 2000-05-05 2009-08-10 Апплайд Резеч Системз Арс Холдинг Н.В. Застосування il-18 як діагностичного маркера серцевої недостатності
AU2002224417A1 (en) * 2000-10-18 2002-04-29 Immunex Corporation Methods for treating il-18 mediated disorders

Also Published As

Publication number Publication date
CA2435466A1 (en) 2002-08-08
HU229164B1 (en) 2013-09-30
NO20033228D0 (no) 2003-07-16
PL213568B1 (pl) 2013-03-29
CN1326562C (zh) 2007-07-18
HUP0303306A3 (en) 2005-12-28
NO331083B1 (no) 2011-10-03
DE60224004T2 (de) 2009-07-23
NO20033228L (no) 2003-09-26
ME00549B (me) 2011-10-10
JP4860897B2 (ja) 2012-01-25
ZA200305439B (en) 2004-07-15
BG66483B1 (bg) 2015-03-31
WO2002060479A1 (en) 2002-08-08
ES2295332T3 (es) 2008-04-16
HK1062810A1 (en) 2004-11-26
ATE380558T1 (de) 2007-12-15
EA010180B1 (ru) 2008-06-30
EP1355668A1 (en) 2003-10-29
PT1355668E (pt) 2008-01-04
IL157024A (en) 2014-02-27
BG108128A (bg) 2004-11-30
MXPA03006776A (es) 2003-10-24
EE200300328A (et) 2003-10-15
JP2004522748A (ja) 2004-07-29
UA80676C2 (en) 2007-10-25
CN1499982A (zh) 2004-05-26
EP1355668B1 (en) 2007-12-12
DE60224004D1 (de) 2008-01-24
JP2009102354A (ja) 2009-05-14
PL366802A1 (en) 2005-02-07
SI1355668T1 (sl) 2008-06-30
EA200501549A1 (ru) 2006-04-28
CA2435466C (en) 2012-04-03
US20040234523A1 (en) 2004-11-25
RS51125B (sr) 2010-10-31
KR20030070143A (ko) 2003-08-27
SK287620B6 (sk) 2011-04-05
CZ305653B6 (cs) 2016-01-27
EA200300844A1 (ru) 2003-12-25
KR100857376B1 (ko) 2008-09-05
CZ20032335A3 (en) 2004-07-14
HRP20030609A2 (en) 2005-06-30
BR0206819A (pt) 2004-02-03
IL157024A0 (en) 2004-02-08
EE05534B1 (et) 2012-04-16
SK10892003A3 (sk) 2004-02-03
HUP0303306A2 (hu) 2004-01-28
YU57803A (sh) 2006-05-25
DK1355668T3 (da) 2008-05-05
EA006767B1 (ru) 2006-04-28
CY1107203T1 (el) 2012-11-21

Similar Documents

Publication Publication Date Title
CY1107203T1 (el) Χρηση αναστολεων της il - 18 για τη θεραπεια και/ή την προληψη καρδιακης νοσου
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
ECSP034774A (es) Pirazolopirimmidinas como agentes terapeuticos
ECSP034773A (es) Pirazolopirimmidinas como agentes terapeuticos
CY1116693T1 (el) Συνδυασμος αζελαστινης και κυκλεσονιδης
AR045179A1 (es) Uso de una combinacion de un inhibidor de la quinasa del receptor del factor de crecimiento epidermico y de agentes citotoxicos para el tratamiento e inhibicion del cancer
CY1109119T1 (el) Φαρμακοτεχνικες μορφες παρατεταμενης απελευθερωσης που περιλαμβανουν λαμοτριγινη
ECSP045407A (es) Benzazoles sustituidos y el uso del mismo como inhibidores de quinasa raf
ECSP044992A (es) Inhibidores de la alquín-aril fosfodiesterasa-4
CY1108748T1 (el) Χρηση αναστολεων της il-18 για την αντιμετωπιση και/η προληψη περιφερικων αγγειακων παθησεων
DK1781277T3 (da) Kombinationssammensætning, der omfatter Ibuprofen og Paracetamol
CY1118924T1 (el) Μεθοδος για θεραπεια της πρωτοπαθους αϋπνιας
SE0101932D0 (sv) Pharmaceutical combinations
SE0302488D0 (sv) New combination
TW200507829A (en) New combination
BRPI0411324A (pt) composições farmacêuticas e métodos de tratamento de resposta mediada por histamina em pacientes
ITRM20030363A0 (it) Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico diesse.
EA200400197A1 (ru) Способы получения поливалентных бактериофагов для лечения бактериальных инфекций
EE200300129A (et) Distamütsiini alfa-halogenoakrüloüülderivaadi kasutamine
AR041595A1 (es) Tratamiento terapeutico
AR043327A1 (es) Uso de inhibidores de quinurenina 3- hidroxilasa para el tratamiento de la diabetes
DE60305053D1 (de) Pyrimidinderivate als selektive cox-2-inhibitoren
ATE306267T1 (de) Kombinationsbehandlung bei akutem myokardinfarkt
CY1106129T1 (el) Κιταλοπραμη για την αγωγη της υψηλης πιεσεως του αιματος
HRPK20040328B3 (en) Pharmaceutical composition comprising gamma-butyrobetaine

Legal Events

Date Code Title Description
FB Suspension of granting procedure